SCHEMBL20704809

SCHEMBL20704809

COc1cc2[nH]cc(C(=O)Nc3ccc(O)cc3)c(=O)c2c(OC)c1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ MAPT P10636 5/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ GFER P55789 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ LMNA P02545 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ MAOB P27338 1/20 0.44
▸ MTNR1A P48039 1/20 0.44
▸ MTNR1B P49286 1/20 0.44
▸ BACE1 P56817 1/20 0.43
▸ CFTR P13569 4/20 0.42
▸ ABCB1 P08183 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704840 0.90 CFTR (0.54) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL30309869 0.90 CFTR (0.54) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL20704836 0.89 MTNR1A (0.47) POLBKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL30309868 0.88 SMN1; SMN2 (0.48) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL20704653 0.88 SMN1; SMN2 (0.48) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL20704823 0.86 CFTR (0.46) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL20704811 0.85 KMT2A (0.52) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL20704802 0.83 MEN1 (0.50) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL30309867 0.83 MEN1 (0.50) POLBKMT2AMEN1RAB9ANPC1
SCHEMBL20704872 0.78 MTNR1A (0.50) POLBKMT2AMEN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-13 — — US disclosed
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-06 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 — — WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 — — US disclosed
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2021-02-25 — — US disclosed
WO-2020227437-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL BIOTHERAPEUTICS, INC. (US) 2020-11-12 — — WO disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
EP-3664822-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID Axial Biotherapeutics, Inc. (US) 2020-06-17 — — EP disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP POLB 3837/4885KMT2A 4786/4885MEN1 4376/4885
US-11505528-B2 Inhibitors of microbially induced amyloid SNCA, PARK7, PRNP POLB 3837/4885KMT2A 4786/4885MEN1 4376/4885
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP POLB 4053/4885KMT2A 4816/4885MEN1 4393/4885
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 POLB 3280/4885KMT2A 3735/4885MEN1 3511/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 POLB 3280/4885KMT2A 3735/4885MEN1 3511/4885
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP POLB 3837/4885KMT2A 4786/4885MEN1 4376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback